A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD

  • STATUS
    Recruiting
  • participants needed
    180
  • sponsor
    GeneScience Pharmaceuticals Co., Ltd.
Updated on 26 September 2022
insulin
body mass index
pituitary
tolerance test
glucocorticoids
pituitary hormone
replacement therapy
other hormones
somatropin
brain injury
peg-rhgh

Summary

This study aims to explore the optimal dose of PEG-rhGH injection in the treatment of AGHD, preliminarily evaluate its safety and efficacy, to provide scientific and reliable evidence for the medication dosage in Phase 2 clinical study.

Details
Condition Adult Growth Hormone Deficiency
Treatment Somatropin Injection
Clinical Study IdentifierNCT03104010
SponsorGeneScience Pharmaceuticals Co., Ltd.
Last Modified on26 September 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note